Revolution Medicines Analyst Price Targets - Benzinga

Revolution Medicines Inc

RVMDNASDAQ

Trade with Public

Trade with Public

$210.02

-0.85-0.4%

In chiusura: Sep 4, 5:00 PM EST

$210.50

0.480.23%

Post-mercato: Sep 4, 4:14 PM EST

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Revolution Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for Revolution Medicines (RVMD).

Price Target Range — 8 Quarters

Analyst Consensus — 21 Analysts

1S.Buy

19Buy

1Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$174Upside to Avg. PT-17.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 31, 2026	Needham	Ami Fadia	PT Raise	Buy	$240→$275
Aug 28, 2026	UBS	Michael Yee	PT Raise	Buy	$220→$265
Aug 28, 2026	Guggenheim	Michael Schmitz	PT Raise	Buy	$240→$275
Aug 27, 2026	Oppenheimer	Jay Olson	PT Raise	Outperform	$230→$260
Aug 27, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$203→$251
Aug 27, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$201→$225
Aug 27, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$231→$239
Aug 27, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$230→$320
Aug 27, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$195→$280
Aug 21, 2026	Bernstein	Jeffrey Walch	PT Raise	Market Perform	$151→$179
Aug 11, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$210→$231
Aug 6, 2026	RBC Capital	Leonid Timashev	PT Raise	Outperform	$182→$203
Aug 6, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$192→$201
Aug 6, 2026	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$220→$230
Aug 6, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$235→$240
Aug 6, 2026	Needham	Ami Fadia	PT Raise	Buy	$236→$240
Jul 23, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$181→$192
Jul 20, 2026	Needham	Ami Fadia	PT Raise	Buy	$235→$236
Jul 9, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$205→$235
Jul 6, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$195

More with Benzinga EdgeGet Access

Analyst Ratings News

Snowflake To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. BMO Capital cut the price

Avi Kapoor

PRO
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $275

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.

Benzinga Newsdesk

PRO
UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265

UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Revolution Medicines, Raises Price Target to $275

Guggenheim analyst Michael Schmitz maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $240 to $275.

Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $230 to $260.

Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $251

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $203 to $251.

Benzinga Newsdesk